Zobrazeno 1 - 10
of 223
pro vyhledávání: '"Juliann, Chmielecki"'
Autor:
Sebastijan Hobor, Maise Al Bakir, Crispin T. Hiley, Marcin Skrzypski, Alexander M. Frankell, Bjorn Bakker, Thomas B. K. Watkins, Aleksandra Markovets, Jonathan R. Dry, Andrew P. Brown, Jasper van der Aart, Hilda van den Bos, Diana Spierings, Dahmane Oukrif, Marco Novelli, Turja Chakrabarti, Adam H. Rabinowitz, Laila Ait Hassou, Saskia Litière, D. Lucas Kerr, Lisa Tan, Gavin Kelly, David A. Moore, Matthew J. Renshaw, Subramanian Venkatesan, William Hill, Ariana Huebner, Carlos Martínez-Ruiz, James R. M. Black, Wei Wu, Mihaela Angelova, Nicholas McGranahan, Julian Downward, Juliann Chmielecki, Carl Barrett, Kevin Litchfield, Su Kit Chew, Collin M. Blakely, Elza C. de Bruin, Floris Foijer, Karen H. Vousden, Trever G. Bivona, TRACERx consortium, Robert E. Hynds, Nnennaya Kanu, Simone Zaccaria, Eva Grönroos, Charles Swanton
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-21 (2024)
Abstract The phenomenon of mixed/heterogenous treatment responses to cancer therapies within an individual patient presents a challenging clinical scenario. Furthermore, the molecular basis of mixed intra-patient tumor responses remains unclear. Here
Externí odkaz:
https://doaj.org/article/a58c4b29e1d8491b8078212067633916
Autor:
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-9 (2023)
Abstract Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimer
Externí odkaz:
https://doaj.org/article/44b83896764b4d85bc01ecb3c4630dd4
Autor:
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki Papadimitrakopoulou
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)
In the phase III AURA3 study (NCT02151981), the third-generation epidermal growth factor receptor tyrosine kinase inhibitor osimertinib prolonged progression-free survival versus platinum-doublet chemotherapy in patients with EGFR T790M advanced NSCL
Externí odkaz:
https://doaj.org/article/97023c9e42e0450eab3688b9d4689761
Autor:
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/9ac77df433144c60bb72e35db443b3df
Autor:
Tereza Vaclova, Ursula Grazini, Lewis Ward, Daniel O’Neill, Aleksandra Markovets, Xiangning Huang, Juliann Chmielecki, Ryan Hartmaier, Kenneth S. Thress, Paul D. Smith, J. Carl Barrett, Julian Downward, Elza C. de Bruin
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
A recent clinical trial shows that a proportion of lung cancer patients carrying the EGFR T790M mutation develop resistance to osimertinib. In this study, the authors show that T790M subclonality is associated with worse clinical outcome likely throu
Externí odkaz:
https://doaj.org/article/481ad63fcd374f3eb7bb421d24c7891e
Autor:
Gerald S Falchook, Jasgit Sachdev, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M Mugundu, Suzanne Jenkins, Juliann Chmielecki, Suzanne Jones, David R Spigel, Melissa Johnson
Publikováno v:
Investigational New Drugs.
Adavosertib selectively inhibits Wee1, which regulates intra-S and G2/M cell-cycle checkpoints. This study investigated dosing schedules for adavosertib monotherapy, determining the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) in
Autor:
Zachary R. Chalmers, Caitlin F. Connelly, David Fabrizio, Laurie Gay, Siraj M. Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki, Franklin Huang, Yuting He, James Sun, Uri Tabori, Mark Kennedy, Daniel S. Lieber, Steven Roels, Jared White, Geoffrey A. Otto, Jeffrey S. Ross, Levi Garraway, Vincent A. Miller, Phillip J. Stephens, Garrett M. Frampton
Publikováno v:
Genome Medicine, Vol 9, Iss 1, Pp 1-14 (2017)
Abstract Background High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or
Externí odkaz:
https://doaj.org/article/fb907a4b3aaf43769173e9ac0018e2eb
Autor:
Javed Khan, Douglas S. Hawkins, Matthew Meyerson, Frederic G. Barr, Stephen X. Skapek, James R. Anderson, Jaume Mora, Gad Getz, Thomas Badgett, Daniel Catchpoole, Sivasish Sindiri, Andrew S. Brohl, Dominik Bogen, Shile Zhang, Hongling Liao, Laura Hurd, Catherine Tolman, Young K. Song, Jianjun Wang, Daniel Auclair, Lauren Ambrogio, Mara Rosenberg, Rajesh Patidar, Jun S. Wei, Juliann Chmielecki, Li Chen, Jack F. Shern
PDF file 186K, Loss of heterozygosity on Chromosome 11p15.5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e45d983aade66abdb5c303e26744e4e3
https://doi.org/10.1158/2159-8290.22530849.v1
https://doi.org/10.1158/2159-8290.22530849.v1
Autor:
Philip J. Stephens, David S. Klimstra, Vincent A. Miller, William Pao, Roman Yelensky, Doron Lipson, Sohail Balasubramanian, Olca Basturk, Jeffrey S. Ross, Siraj M. Ali, Julia Elvin, Chanjuan Shi, Adrienne Johnson, Zachary R. Chalmers, Garrett M. Frampton, Katherine E. Hutchinson, Juliann Chmielecki
Supplementary Table S3: Genomic alterations across selected targets. See Figure 3 for additional details. Zoomable PDF.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::730dc91166d6461a5ebeffa3ca2de1bf
https://doi.org/10.1158/2159-8290.22530626
https://doi.org/10.1158/2159-8290.22530626
Autor:
Javed Khan, Douglas S. Hawkins, Matthew Meyerson, Frederic G. Barr, Stephen X. Skapek, James R. Anderson, Jaume Mora, Gad Getz, Thomas Badgett, Daniel Catchpoole, Sivasish Sindiri, Andrew S. Brohl, Dominik Bogen, Shile Zhang, Hongling Liao, Laura Hurd, Catherine Tolman, Young K. Song, Jianjun Wang, Daniel Auclair, Lauren Ambrogio, Mara Rosenberg, Rajesh Patidar, Jun S. Wei, Juliann Chmielecki, Li Chen, Jack F. Shern
PDF file 92K, Supplementary Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a80ec84c5c621df249ba20296279c17
https://doi.org/10.1158/2159-8290.22530840.v1
https://doi.org/10.1158/2159-8290.22530840.v1